Current Cardiomyopathy Clinical Trials and Research Studies
There are many ways to participate in clinical trials or research studies depending on your comfort level. Below you will find some of the many trials currently being done.
To learn about other current trials that may not be listed below, go to ClinicalTrials.gov. Click on Advanced Search, type in your search criteria (e.g. condition, state, age group etc.) and hit enter.
At the bottom of the page you will also find a brief slideshow created by smallbeats called "From Chemical Compound to Countertop" that goes through the clinical trial process.
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I or II, clinically stable HCM patient volunteers aged 18-65 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02329184
This trial is currently active but not recruiting. The next phase of this trial will begin later in 2016.
Contact: Susan Szambelan 508.404.3454 firstname.lastname@example.org
Lifestyle and Exercise in Hypertrophic Cardiomyopathy (LIVE-HCM)
The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS).
Please refer to this study by its ClinicalTrials.gov identifier: NCT02549664
Yale cardiomyopathy index
About the study
The Yale Cardiomyopathy Index is an exciting iPhone-based clinical study for people in the United States aged 2 to 80 years who have a cardiomyopathy or are at increased risk for developing one. This study is one of the first to be designed with the assistance of Apple's ResearchKit software.
With the Yale Cardiomyopathy Index app, eligible individuals contribute self-assessments of their Quality of Life across multiple domains and perform 6-minute walks to assess peak distance covered and heart rate trends. Educational resources to assist in understanding these conditions are available within the application.
This study, approved by the Yale University Institutional Review Board, is the first to use ResearchKit and HealthKit to better understand the issues affecting children and young adults. With a parent or guardian’s permission and co-participation, children as young as 8 years of age provide an assessment of how their cardiomyopathy or their risk of developing a cardiomyopathy affects their daily lives. Parents of those 2 to 8 years of age can take part on their own with tailored questionnaires designed to assess how a cardiomyopathy affects their younger child. Adults between 18 and 80 years may take part on their own. Multiple people from the same family can take part simultaneously within this app.
Click here for more information and to download the free app.
HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonanceimaging and blood draw for genetics and biomarkers
Please refer to this study by its ClinicalTrials.gov identifier: NCT01915615
Visit Clinicaltrials.gov to see full list of study locations
VANISH: A study for people with HYPERTROPHIC CARDIOMYOPATHY?
The researchers participating in this trial are interested in learning whether a medication called valsartan can be used to slow the progression of HCM. Valsartan is FDA approved to treat high blood pressure, but it has not been previously been tested for treating HCM in this manner.
The study will last for approximately two years and includes taking a pill (valsartan or inactive sugar pill) twice a day for approximately two years. Participants will be asked to come to the hospital up to seven times over the two year period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01912534
Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM)
This study will evaluate the effect of GS-6615 on exercise capacity, quality of life, and safety and tolerability of GS-6615 in participants with symptomatic hypertrophic cardiomyopathy (HCM).
Please refer to this study by its ClinicalTrials.gov identifier: NCT02291237
Contact: Gilead Study Team email@example.com
Genetic Predictors of Outcome in HCM Patients
This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies. Genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-AR polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as LVH in patients with HCM and whether these polymorphisms influence the clinical course and outcome in patients with HCM. For that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with HCM that have regular follow up and test them for beta-AR polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with HCM.
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious. Cardiomyopathy in children can result in death, disability, heart transplantation or serious heart rhythm disorders. Natural substances in the blood called cardiac biomarkers can be measured in the laboratory and could be a less invasive way (compared to echocardiograms or MRIs) to detect heart dysfunction in children with cardiomyopathy. Little is known about how useful and valid cardiac biomarkers are in the diagnosis and determination of the symptoms in children with cardiomyopathy. The longterm goal of this project is to study how helpful measuring cardiac biomarkers in children with cardiomyopathy is to their doctors in managing the care of these patients as well as improving their overall health. Measures of these cardiac biomarkers could help doctors in determining how best to care for a child with cardiomyopathy, includingwhen to consider heart transplantation as a treatment option.
Please refer to this trial by it's ClinicalTrials.gov identifier: NCT01873976
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCMGENES)
Cardiomyopathy in children is a serious disease which can result in death, disability, heart transplantation or serious heart rhythm disorders. Doctors know little about the causes of cardiomyopathy but would like to learn more. In fact, up to 50-75% of cases in children have no known cause. For this reason, the purpose of this study is to identify genes that cause cardiomyopathy or that influence how people with cardiomyopathy do over time. These findings could improve disease prevention, surveillance, early management, and prognosis.
ClinicalTrials.gov identifier: NCT01873963
Hypertrophic Regression With N-Acetylcysteine in HCM (HALT)
The purpose of the sudy is to conduct a small study to gather the preliminary data for future lage scale clinical studies that will be designed test the potential beneficial efffect of over-the counter study anti-oxidant drug called N-acetylcysteine (NAC) in patients with a heart muscle condition called Hypertrophic Cardiomyopathy (HCM). The present study is a pilot feasibility study, the investigators want to find out whether the investigators can recruit and retain patients with HCM in the study and whether these patients can tolerate this drug and can stay on one year. Likewise, the investigators want to find out any potential side effects that this drug might have and estimate whether ii has any beneficial effects.
ClinicalTrials.gov identifier: NCT01537926
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.
ClinicalTrials.gov identifier: NCT02234336
Biomarkers in Aortic Stenosis - B.A.S.S.
This study is being done to determine whether or not new blood test(s) can determine the severity of heart conditions. Aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, aortic regurgitation, artificial heart valve regurgitation or stenosis, and tricuspid valve regurgitation associated with pacemaker leads are the cardiac disorders under study. The blood tests involve analysis for von Willebrand Factor antigen and activity, von Willebrand Factor multimers, and brain natriuretic peptide (BNP) levels. The results of the blood tests will be compared to the information from the clinically-indicated echocardiogram and one blood test compared to another.
ClinicalTrials.gov identifier: NCT01334801
Pediatric Cardiomyopathy Mutation Analysis
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.
ClinicalTrials.gov identifier: NCT02432092
Perfusion Imaging With Myocardial Contrast Echocardiography in HCM
The objective of this study is to determine whether myocardial contrast echocardiography in patients with cardiomyopathy (HCM) can detect resting hypo-perfusion due to fibrosis or stress induced perfusion defects due to associated abnormalities in intramyocardial arteries and the microcirculation. A secondary aim will be to determine whether abnormalities in perfusion are associated with either severity of symptoms (chest pain and dyspnea), presence of arrhythmias, and regional functionof the septum.
ClinicalTrials.gov identifier: NCT02560467
Used with permission by smallbeats.